PT3177640T - Agentes pd-1 de alta afinidade e métodos de utilização - Google Patents

Agentes pd-1 de alta afinidade e métodos de utilização

Info

Publication number
PT3177640T
PT3177640T PT158296525T PT15829652T PT3177640T PT 3177640 T PT3177640 T PT 3177640T PT 158296525 T PT158296525 T PT 158296525T PT 15829652 T PT15829652 T PT 15829652T PT 3177640 T PT3177640 T PT 3177640T
Authority
PT
Portugal
Prior art keywords
agents
methods
high affinity
affinity
Prior art date
Application number
PT158296525T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of PT3177640T publication Critical patent/PT3177640T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
PT158296525T 2014-08-08 2015-08-07 Agentes pd-1 de alta afinidade e métodos de utilização PT3177640T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462035316P 2014-08-08 2014-08-08
US201562150789P 2015-04-21 2015-04-21

Publications (1)

Publication Number Publication Date
PT3177640T true PT3177640T (pt) 2020-08-31

Family

ID=55264785

Family Applications (1)

Application Number Title Priority Date Filing Date
PT158296525T PT3177640T (pt) 2014-08-08 2015-08-07 Agentes pd-1 de alta afinidade e métodos de utilização

Country Status (13)

Country Link
US (5) US9546206B2 (OSRAM)
EP (2) EP3177640B1 (OSRAM)
JP (1) JP6945444B2 (OSRAM)
CN (1) CN107108707A (OSRAM)
CA (1) CA2994927A1 (OSRAM)
CY (1) CY1123385T1 (OSRAM)
DK (1) DK3177640T3 (OSRAM)
ES (1) ES2819451T3 (OSRAM)
HR (1) HRP20201153T1 (OSRAM)
HU (1) HUE050406T2 (OSRAM)
PL (1) PL3177640T3 (OSRAM)
PT (1) PT3177640T (OSRAM)
WO (1) WO2016022994A2 (OSRAM)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100615A1 (en) 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
ES2819451T3 (es) * 2014-08-08 2021-04-16 Univ Leland Stanford Junior Agentes PD-1 de alta afinidad y procedimientos de uso
CA2961987A1 (en) 2014-09-30 2016-04-07 Intervet International B.V. Pd-l1 antibodies binding canine pd-l1
US11229713B2 (en) 2014-11-25 2022-01-25 Bristol-Myers Squibb Company Methods and compositions for 18F-radiolabeling of biologics
CN114591420A (zh) 2014-11-25 2022-06-07 百时美施贵宝公司 用于成像的新型pd-l1结合多肽
EP3549612B1 (en) * 2015-03-02 2025-04-30 Innovative Cellular Therapeutics Holdings, Ltd. Reducing immune tolerance induced by pd-l1
IL304950A (en) * 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
EP3466967A1 (en) 2015-05-18 2019-04-10 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
BR112018000768A2 (pt) 2015-07-13 2018-09-25 Cytomx Therapeutics Inc anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
NZ739503A (en) 2015-07-16 2023-06-30 Bioxcel Therapeutics Inc A novel approach for treatment of cancer using immunomodulation
US10259859B2 (en) 2015-08-07 2019-04-16 ALX Oncology Inc. Constructs having a SIRP-α domain or variant thereof
KR20180063885A (ko) * 2015-09-24 2018-06-12 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 전이 감소를 위한 방법 및 조성물
US12282014B2 (en) 2015-11-19 2025-04-22 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
IL310729A (en) 2016-04-15 2024-04-01 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
WO2017181148A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
WO2017200796A1 (en) 2016-05-17 2017-11-23 Albert Einstein College Of Medicine, Inc. Engineered pd-1 variants
WO2017210302A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Pet imaging with pd-l1 binding polypeptides
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
RU2656181C1 (ru) * 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
CN118085109A (zh) 2016-08-11 2024-05-28 昆士兰医学研究所理事会 免疫调节化合物
WO2018067361A1 (en) * 2016-10-04 2018-04-12 The Curators Of The University Of Missouri Peptides for molecular detection of pd-l1
BR112019007100A2 (pt) 2016-10-07 2019-06-25 Tcr2 Therapeutics Inc composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
BR112019008494A2 (pt) 2016-11-02 2019-07-09 Jounce Therapeutics Inc anticorpos para pd-1 e usos dos mesmos
CN110072870A (zh) 2016-11-09 2019-07-30 健康之语公司 预组装的、受保护的、化学稳定的化学选择性接头
US11359112B2 (en) 2016-11-09 2022-06-14 Cowper Sciences Inc. Coatings with tunable amine density
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
BR112019011186A2 (pt) 2016-12-01 2019-10-08 Regeneron Pharmaceuticals, Inc. conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor.
KR102597943B1 (ko) * 2017-01-05 2023-11-06 카 메디컬 리미티드 Pd1-41bbl 융합 단백질 및 이의 이용 방법
WO2018127916A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
HUE057326T2 (hu) 2017-01-05 2022-04-28 Kahr Medical Ltd SIRP1 Alfa-41 BBL fúziós fehérje és eljárások annak alkalmazására
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
CA3051481A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
CN110650974B (zh) 2017-02-10 2024-04-19 瑞泽恩制药公司 用于免疫-pet成像的放射性标记的抗-lag3抗体
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
US11732022B2 (en) 2017-03-16 2023-08-22 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
IL268781B2 (en) 2017-03-16 2025-09-01 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
WO2018183488A1 (en) * 2017-03-28 2018-10-04 Ohio State Innovation Foundation Human pd1 peptide vaccines and uses thereof
WO2018192443A1 (zh) * 2017-04-17 2018-10-25 中国科学院苏州纳米技术与纳米仿生研究所 一种多肽及其应用
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
EP4509132A3 (en) * 2017-05-26 2025-11-19 The Johns Hopkins University Multifunctional antibody-ligand traps to modulate immune tolerence
JP7304846B2 (ja) 2017-07-24 2023-07-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｃｄ８抗体およびその使用
WO2019040098A1 (en) * 2017-08-21 2019-02-28 Dana-Farber Cancer Institute, Inc. METHODS OF MODULATING THE INTERACTION BETWEEN BAF COMPLEXES AND EWS-FLI1
CA3198255A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
US11802153B2 (en) 2017-10-18 2023-10-31 Forty Seven, Inc. Anti-CD47 agent-based ovarian cancer therapy
EA202090974A1 (ru) 2017-10-18 2020-08-05 Элпайн Иммьюн Сайенсиз, Инк. Вариантные иммуномодулирующие белки лиганда icos и сопутствующие композиции и способы
CN107916255B (zh) * 2017-11-16 2021-06-04 复旦大学 Pdl-1基因靶向特异性甲基化表观遗传修饰抗肿瘤分子及其用途
WO2019136179A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
JP7549303B2 (ja) 2018-01-22 2024-09-11 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞の使用方法
EP3746124A4 (en) 2018-01-30 2021-10-27 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
CN111936518A (zh) 2018-02-06 2020-11-13 西雅图儿童医院（Dba西雅图儿童研究所） 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
CN108794619B (zh) * 2018-05-31 2021-09-17 郑州大学 一种高亲和pd-1蛋白突变体
WO2019227490A1 (en) * 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
US11987629B2 (en) 2018-06-01 2024-05-21 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and uses thereof for treating disease or condition
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
CA3104780A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
CA3104778A1 (en) * 2018-07-11 2020-01-16 Kahr Medical Ltd. Pd1-4-1bbl variant fusion protein and methods of use thereof
CN108997492B (zh) * 2018-07-19 2022-04-12 海珂分子（北京）科技有限责任公司 高亲和力的pd1胞外区突变体多肽及相关融合蛋白
SG11202101904UA (en) * 2018-09-14 2021-04-29 Univ Leland Stanford Junior Spd-1 variant - fc fusion proteins
WO2020068500A1 (en) * 2018-09-26 2020-04-02 Albert Einstein College Of Medicine Mutant variants of pd-1 receptor with selective binding to pd-l1 and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020102365A1 (en) * 2018-11-14 2020-05-22 Healthtell Inc. Methods of selecting functional interface mimics, and compositions thereof
SG11202104675TA (en) 2018-11-21 2021-06-29 Mayo Found Medical Education & Res Adenoviruses and methods for using adenoviruses
CN111100199B (zh) * 2018-12-29 2021-02-12 北京百普赛斯生物科技股份有限公司 一种荧光素标记的蛋白四聚体及其制备方法与应用
CN113795511B (zh) 2019-01-23 2024-07-23 大有华夏生物医药集团有限公司 抗pd-l1双抗体及其用途
WO2020160196A1 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
CN111714618B (zh) * 2019-03-22 2024-07-12 香雪生命科学技术（广东）有限公司 T细胞和高亲和力pd-1融合蛋白的组合
CN110054701B (zh) * 2019-04-17 2022-12-27 中国医学科学院血液病医院（血液学研究所） 一种基于间充质干细胞的抗肿瘤靶向给药系统及其应用
CA3138527C (en) 2019-04-29 2024-03-12 Mayo Foundation For Medical Education And Research Multivalent pd-l1 binding compounds for treating cancer
CN114007640A (zh) 2019-05-01 2022-02-01 朱诺治疗学股份有限公司 从修饰的cd247基因座表达嵌合受体的细胞、相关多核苷酸和方法
US20220184131A1 (en) 2019-05-01 2022-06-16 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
CN119700933A (zh) 2019-05-31 2025-03-28 Alx肿瘤生物技术公司 用SIRPαFc融合体组合免疫检查点抑制剂治疗癌症的方法
CN112279923B (zh) * 2019-07-22 2023-07-18 南京助天中科科技发展有限公司 一种嵌合抗原受体及其应用
WO2021097278A1 (en) * 2019-11-14 2021-05-20 Ludwig Institute For Cancer Research Ltd Compositions and methods for immunotherapy
JP7650047B2 (ja) * 2019-11-27 2025-03-24 株式会社 MiyaCare Therapeutics 変異型結合性タンパク質の製造方法及び変異型ｐｄ－１
BR112022015004A2 (pt) 2020-01-29 2022-09-20 Foghorn Therapeutics Inc Composto, composição farmacêutica, métodos para diminuir a atividade de um complexo baf, induzir apoptose, reduzir o crescimento tumoral, suprimir a progressão e a colonização metastática do câncer e reduzir o nível e/ou a atividade de brg1 e/ou brm em um câncer e métodos de tratamento e de inibição de brm e brg1
KR102623161B1 (ko) * 2020-10-08 2024-01-09 고려대학교 산학협력단 Pd-l1 친화도가 증가된 pd-1 변이체
CN115515973B (zh) * 2020-05-06 2025-12-12 高丽大学校产学协力团 增加pd-l1亲和度的pd-1变异体
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
US20230218777A1 (en) * 2020-05-28 2023-07-13 The Board Of Trustees Of The Leland Stanford Junior University Aerosolized mucus-tethering nanobodies to protect against viral and microbial contamination in closed and semi-enclosed spaces
KR20230042283A (ko) 2020-06-26 2023-03-28 주노 테라퓨틱스 게엠베하 재조합 수용체를 조건부로 발현하는 조작된 ｔ 세포, 관련된 폴리뉴클레오티드 및 방법
US20230414660A1 (en) * 2020-11-13 2023-12-28 Ludwig Institute For Cancer Research Ltd Pd-1 decoy variants for immunotherapy
CN112999368A (zh) * 2021-04-09 2021-06-22 广东药康生物科技有限公司 人源化模型进行药效评价方法的建立
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
WO2023097313A1 (en) * 2021-11-26 2023-06-01 Vita Therapeutics, Inc. Immune cell therapy of pd-l1 positive cancers
CN117777303A (zh) * 2022-09-27 2024-03-29 北京大学 一种高亲和力pd1蛋白偶联物及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DK0648271T3 (da) 1991-08-20 2003-07-21 Us Gov Health & Human Serv Adenovirusmedieret overførsel af gener til mave-/tarmkanal
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
JPH07291996A (ja) 1994-03-01 1995-11-07 Yuu Honshiyo ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
EP1083231A1 (en) 1999-09-09 2001-03-14 Introgene B.V. Smooth muscle cell promoter and uses thereof
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7169874B2 (en) 2001-11-02 2007-01-30 Bausch & Lomb Incorporated High refractive index polymeric siloxysilane compositions
KR101607288B1 (ko) * 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA023148B1 (ru) * 2008-08-25 2016-04-29 Эмплиммьюн, Инк. Композиции на основе антагонистов pd-1 и их применение
US20110159023A1 (en) * 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
JP5520961B2 (ja) 2008-11-28 2014-06-11 エモリー ユニバーシティ 感染症および腫瘍を処置するための方法
US20110189743A1 (en) * 2009-10-06 2011-08-04 Bio Architecture Lab, Inc. Microbial systems for producing commodity chemicals
CN107090029B (zh) * 2010-11-11 2021-07-13 港大科桥有限公司 可溶性 pd-1变体、融合构建体及其用途
JP6130307B2 (ja) 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム 再指向性免疫療法
DK2699264T3 (en) * 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
BR122022000334B1 (pt) * 2011-08-01 2023-03-21 Genentech, Inc Composição farmacêutica compreendendo um antagonista de ligação ao eixo pd-1 e um inibidor de mek
US8956619B2 (en) * 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
SMT202000689T1 (it) 2012-01-17 2021-01-05 Univ Leland Stanford Junior Reagenti per sirp-alfa ad alta affinita'
EP2807194A4 (en) 2012-01-27 2015-12-02 Gliknik Inc FUSION PROTEINS WITH IGG2 HINGEOMS
DK3473707T3 (da) 2012-05-25 2025-03-17 Cellectis Fremgangsmåder til engineering af allogen og immunsuppressiv resistent t-celle til immunoterapi
EP2890715B1 (en) * 2012-08-03 2020-12-16 Dana-Farber Cancer Institute, Inc. Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
CN104853766A (zh) 2012-10-02 2015-08-19 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
CA2894245C (en) 2012-12-17 2022-03-22 Trillium Therapeutics Inc. Treatment of cd47+ disease cells with sirp alpha-fc fusions
WO2014124217A1 (en) 2013-02-07 2014-08-14 Albert Einstein College Of Medicine Of Yeshiva University A selective high-affinity immune stimulatory reagent and uses thereof
MY175869A (en) 2013-02-26 2020-07-14 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
ES2819451T3 (es) * 2014-08-08 2021-04-16 Univ Leland Stanford Junior Agentes PD-1 de alta afinidad y procedimientos de uso
DK3298043T3 (da) * 2015-05-18 2021-02-15 Ab Initio Biotherapeutics Inc SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse

Also Published As

Publication number Publication date
US20240174729A1 (en) 2024-05-30
WO2016022994A2 (en) 2016-02-11
US9546206B2 (en) 2017-01-17
CN107108707A (zh) 2017-08-29
EP3177640B1 (en) 2020-05-06
EP3177640A4 (en) 2018-01-03
EP3177640A2 (en) 2017-06-14
DK3177640T3 (da) 2020-08-10
HUE050406T2 (hu) 2020-12-28
PL3177640T3 (pl) 2020-11-02
CY1123385T1 (el) 2021-12-31
EP3699189A1 (en) 2020-08-26
WO2016022994A9 (en) 2017-05-11
CA2994927A1 (en) 2016-02-11
US10800830B2 (en) 2020-10-13
US11814419B2 (en) 2023-11-14
US20160039903A1 (en) 2016-02-11
US20210040176A1 (en) 2021-02-11
JP6945444B2 (ja) 2021-10-06
US9562087B2 (en) 2017-02-07
JP2017525354A (ja) 2017-09-07
WO2016022994A3 (en) 2016-05-06
US20160052990A1 (en) 2016-02-25
HRP20201153T1 (hr) 2021-01-22
ES2819451T3 (es) 2021-04-16
US20170233451A1 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
IL286316A (en) New micro-dystrophins and related method of use
HUE050406T2 (hu) Nagy affinitású PD-1 hatóanyag és alkalmazási módszerek
IL250415B (en) Antibodies against pd-l and methods of using them
IL258768A (en) Compounds interacting with glycans and methods of use
IL251868B (en) Anti-tim3 antibodies and methods of use
IL251970A0 (en) Anti-cd79b antibodies and methods of use
HUE068842T2 (hu) Vegyületek és alkalmazási eljárásaik
IL246736A0 (en) Anti-jagged1 antibodies and methods of use
HUE061672T2 (hu) Glikán-interakcióban lévõ vegyületek és felhasználási módszerek
HUE050761T2 (hu) Vegyületek és alkalmazási eljárások
ZA201701909B (en) Trichoderma compositions and methods of use
IL251165A0 (en) Anti-il-1beta antibodies and methods of their use
SG11201708114SA (en) Ophthalmic compositions and methods of use therefor
IL251286A0 (en) Anti-pdgf-b antibodies and methods of use
EP3350196C0 (en) CARBORANE COMPOUNDS AND METHODS OF USE THEREOF
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
ZA201606450B (en) Compounds and their methods of use
GB201403697D0 (en) Compounds and methods of use
GB201416797D0 (en) Contianer and method of use thereof